Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions - Cancer Currents Blog

National Cancer Institute sent this bulletin at 02/20/2024 10:36 AM EST

Having trouble viewing this email? View it as a Web page.

Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions
02/16/2024
	The results of the clinical trial that led to FDA’s 2023 approval of repotrectinib (Augtyro) for lung cancers with ROS1 fusions have been published. The drug shrank tumors in 80% of people receiving the drug as an initial treatment.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.